Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Dupilumab, administered by subcutaneous injection, is the first targeted treatment to be approved in the United States for bullous pemphigoid, according to the company’s press release.

TOPLINE: Treating atopic dermatitis (AD) with dupilumab vs other systemic agents increased the risk of developing psoriasis over 3 years, a cohort study found. METHODOLOGY: Addressing ...

In the trial, Dupixent ® (dupilumab) outperformed Xolair ® (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints.

DC-15442 is a potent small molecule STAT6 inhibitor, which is not a degrader or prodrug, being advanced as a safe dupilumab-in-a-pill alternative for patients BOSTON, June 10, 2025 /PRNewswire ...

Importantly, like dupilumab, DC-15442 does not degrade STAT6 proteins or impair uSTAT6 non-inflammatory functions. Therefore, DC-15442 does not have the on-target safety concerns of potential ...

Govt exempts imported medical-grade plastic from quality rules to boost syringe, IV production Facing a sharp drop in imports and rising pressure from the medical device industry, the government ...

To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.

A total of 145 people reported they had been jabbed with syringes, according to the French interior ministry, as the country celebrated Fête de la Musique, a free nationwide music festival.

Ahead of the festival, influencers warned that calls had been made to target women with syringe attacks. RELATED: GBV at universities ‘rooted in socialisation, entitlement and toxic masculinity’ ...

TARRYTOWN, N.Y. and PARIS, June 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with ...